Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 458

1.

Treatment of Chronic Myeloid Leukemia in Rural Rwanda: Promising Early Outcomes.

Tapela N, Nzayisenga I, Sethi R, Bigirimana JB, Habineza H, Hategekimana V, Mantini N, Mpunga T, Shulman LN, Lehmann L.

J Glob Oncol. 2016 Feb 3;2(3):129-137. doi: 10.1200/JGO.2015.001727. eCollection 2016 Jun.

2.

Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach.

Keramatinia A, Ahadi A, Akbari ME, Mohseny M, Jarahi AM, Mehrvar N, Mansouri N, Tabatabaei SAM, Movafagh A.

J Cancer Prev. 2017 Jun;22(2):74-81. doi: 10.15430/JCP.2017.22.2.74. Epub 2017 Jun 30. Review.

3.

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia.

Shea LK, Mikhail FM, Forero-Torres A, Davis RS.

Clin Case Rep. 2017 Apr 24;5(6):899-901. doi: 10.1002/ccr3.974. eCollection 2017 Jun.

4.

Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies.

Blumenthal GM, Kluetz PG, Schneider J, Goldberg KB, McKee AE, Pazdur R.

Oncologist. 2017 Jul;22(7):762-767. doi: 10.1634/theoncologist.2017-0152. Epub 2017 Jun 2. No abstract available.

5.

Morphological Changes in Bone Marrow Post Imatinib Therapy in Chronic Phase CML: A Follow up Study on Sequential Bone Marrow Aspirates and Biopsies.

Narang NC, Rusia U, Sikka M, Kotru M.

J Clin Diagn Res. 2017 Apr;11(4):EC25-EC29. doi: 10.7860/JCDR/2017/25173.9650. Epub 2017 Apr 1.

6.

Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia.

Togasaki E, Takeda J, Yoshida K, Shiozawa Y, Takeuchi M, Oshima M, Saraya A, Iwama A, Yokote K, Sakaida E, Hirase C, Takeshita A, Imai K, Okumura H, Morishita Y, Usui N, Takahashi N, Fujisawa S, Shiraishi Y, Chiba K, Tanaka H, Kiyoi H, Ohnishi K, Ohtake S, Asou N, Kobayashi Y, Miyazaki Y, Miyano S, Ogawa S, Matsumura I, Nakaseko C, Naoe T.

Blood Cancer J. 2017 Apr 28;7(4):e559. doi: 10.1038/bcj.2017.36.

7.

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML.

Valent P, Herndlhofer S, Schneeweiß M, Boidol B, Ringler A, Kubicek S, Gleixner KV, Hoermann G, Hadzijusufovic E, Müllauer L, Sperr WR, Superti-Furga G, Mannhalter C.

Oncotarget. 2017 Apr 4;8(14):23061-23072. doi: 10.18632/oncotarget.15481.

8.

Targeted therapy for soft tissue sarcomas in adolescents and young adults.

Steppan DA, Pratilas CA, Loeb DM.

Adolesc Health Med Ther. 2017 Mar 30;8:41-55. doi: 10.2147/AHMT.S70377. eCollection 2017. Review.

9.

Tyrosine kinase-targeting drugs-associated heart failure.

Gronich N, Lavi I, Barnett-Griness O, Saliba W, Abernethy DR, Rennert G.

Br J Cancer. 2017 May 9;116(10):1366-1373. doi: 10.1038/bjc.2017.88. Epub 2017 Apr 11.

PMID:
28399109
10.

Drug Development Against Metastatic Cancers.

Wang C, Huang S.

Yale J Biol Med. 2017 Mar 29;90(1):119-123. eCollection 2017 Mar. Review.

11.

Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.

Alikian M, Gale RP, Apperley JF, Foroni L.

Biomol Detect Quantif. 2017 Feb 14;11:4-20. doi: 10.1016/j.bdq.2017.01.001. eCollection 2017 Mar. Review.

12.

Liquid Chromatography-Mass Spectrometry/Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague-Dawley Rats.

Wang P, Peng Y, Zhang X, Fei F, Wang S, Feng S, Huang J, Wang H, Aa J, Wang G.

Oncol Ther. 2016;4(1):117-128. doi: 10.1007/s40487-016-0022-2. Epub 2016 Jun 6.

13.

Performance of Sokal and Eutos Scores for Predicting Cytogenetic and Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients on Imatinib.

Ganguly S, Lakshmaiah KC, Jacob LA, Babu S, Dasappa L, Govind Babu KS.

Indian J Hematol Blood Transfus. 2017 Mar;33(1):82-86. doi: 10.1007/s12288-016-0667-x. Epub 2016 Mar 14.

PMID:
28194061
14.

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.

Warfvinge R, Geironson L, Sommarin MNE, Lang S, Karlsson C, Roschupkina T, Stenke L, Stentoft J, Olsson-Strömberg U, Hjorth-Hansen H, Mustjoki S, Soneji S, Richter J, Karlsson G.

Blood. 2017 Apr 27;129(17):2384-2394. doi: 10.1182/blood-2016-07-728873. Epub 2017 Jan 25.

15.

Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects.

Ault PS, Rose PharmD J, Nodzon PhD LA, Kaled ES.

J Adv Pract Oncol. 2016 Mar;7(2):160-175. Epub 2016 Mar 1. Review.

16.

Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib.

Ailawadhi S, Akard LP, Miller CB, Jillella A, DeAngelo DJ, Ericson SG, Lin F, Warsi G, Radich J.

Ther Adv Hematol. 2017 Jan;8(1):3-12. doi: 10.1177/2040620716678118. Epub 2016 Nov 24.

17.

Phylooncogenomics: Examining the cancer genome in the context of vertebrate evolution.

Zhang G, Vemulapalli TH, Yang JY.

Appl Transl Genom. 2013 Jun 29;2:48-54. eCollection 2013 Dec 1. Review.

18.

Approaches to modernize the combination drug development paradigm.

Day D, Siu LL.

Genome Med. 2016 Oct 28;8(1):115. Review.

19.

Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia.

Huang J, Wang L, Chen L, Qun H, Yajing X, Fangping C, Xielan Z.

Turk J Haematol. 2017 Mar 1;34(1):10-15. doi: 10.4274/tjh.2016.0156. Epub 2016 Oct 18.

20.

Direct effect of dasatinib on signal transduction pathways associated with a rapid mobilization of cytotoxic lymphocytes.

Iriyama N, Hatta Y, Takei M.

Cancer Med. 2016 Nov;5(11):3223-3234. doi: 10.1002/cam4.925. Epub 2016 Oct 10.

Supplemental Content

Support Center